Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
03. März 2022 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting
02. März 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference
21. Februar 2022 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma
17. Februar 2022 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results
10. Januar 2022 05:50 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
22. Dezember 2021 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
18. November 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression
17. November 2021 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Reports Third Quarter 2021 Financial Results
10. November 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
10. November 2021 16:04 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...